{"id":584757,"date":"2022-02-02T19:28:01","date_gmt":"2022-02-02T19:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=584757"},"modified":"2022-02-02T19:28:01","modified_gmt":"2022-02-02T19:28:01","slug":"pemphigus-vulgaris-market-is-expected-to-showcase-a-significant-growth-by-2032-estimates-delveinsight-key-companies-principia-biopharma-topas-therapeutics-and-argenx-bvba","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pemphigus-vulgaris-market-is-expected-to-showcase-a-significant-growth-by-2032-estimates-delveinsight-key-companies-principia-biopharma-topas-therapeutics-and-argenx-bvba_584757.html","title":{"rendered":"Pemphigus Vulgaris Market is Expected to Showcase a Significant Growth by 2032, Estimates DelveInsight | Key Companies &#8211; Principia Biopharma, Topas Therapeutics, and Argenx BVBA"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pemphigus Vulgaris Market is Expected to Showcase a Significant Growth by 2032, Estimates DelveInsight | Key Companies - Principia Biopharma, Topas Therapeutics, and Argenx BVBA\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Pemphigus Vulgaris Market is Expected to Showcase a Significant Growth by 2032, Estimates DelveInsight | Key Companies - Principia Biopharma, Topas Therapeutics, and Argenx BVBA\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Pemphigus Vulgaris Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Pemphigus Vulgaris market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Pemphigus Vulgaris Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/de907fc16c997951a99e9da049fb6915.jpg\" alt=\"Pemphigus Vulgaris Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pemphigus Vulgaris: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Pemphigus Vulgaris (PV) is a rare, severe autoimmune and intraepithelial disease characterized by flaccid blisters and erosions of the skin and mucous membrane. It is histologically marked by acantholysis and is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Pemphigus Vulgaris Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>As per DelveInsight, the total diagnosed prevalent cases of Pemphigus Vulgaris in the 7MM were observed to be 42,400+ in 2020.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>The estimates show the highest diagnosed prevalence of Pemphigus Vulgaris in the United States with 14,000+ cases in 2020.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>Among the EU5 countries, Germany had the highest diagnosed prevalent population of Pemphigus Vulgaris with 7,600+ cases, followed by the United Kingdom with 6,900+ cases. On the other hand, France had the lowest diagnosed prevalent population of 2,600+ in 2020.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>A female predominance in Pemphigus Vulgaris is well established. However, the genetic and physiological basis for this gender bias is not well understood.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>PV is five times as prevalent as Pemphigus Foliaceous in the US. Desmoglein (Dsg) 3 is the major antigen in PV but 50&ndash;60% of patients have additional antibodies to Dsg1. The underlying antibody profile is the major determinant of the clinical phenotype.<\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get the Sample PDF&nbsp;of the Report:-&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pemphigus-vulgaris-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pemphigus-vulgaris-market<\/a><\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Pemphigus Vulgaris Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides an in-depth analysis of <strong>Pemphigus Vulgaris Market Size and Share<\/strong> till 2032 in the 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report will help in developing business strategies by understanding the Pemphigus Vulgaris Market Trends, key players, and ongoing developments activities, that shape and drive the market growth in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It covers <strong>Pemphigus Vulgaris&#8217; current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in the 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the <strong>Pemphigus Vulgaris market<\/strong> in terms of market drivers &amp; barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pemphigus-vulgaris-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Pemphigus Vulgaris Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><em>As per DelveInsight, the <strong>Pemphigus Vulgaris market<\/strong> is expected to grow by factors like an increase in the prevalent pool, rising awareness among patients, the recent approval of MabThera\/Rituxan, and the expected entry of emerging therapies.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted <strong>Pemphigus Vulgaris market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Pemphigus Vulgaris market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pemphigus Vulgaris Epidemiology Forecast&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section covers insights about the historical and current <strong>Pemphigus Vulgaris patient pool and forecasted trends<\/strong> for every seven major countries (7MM)&nbsp; from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pemphigus Vulgaris (PV) Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Diagnosed Prevalent Cases of PV<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Age-specific Diagnosed Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gender-specific Diagnosed Prevalent Cases of PV<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Severity-specific Diagnosed Prevalent Cases of PV<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pemphigus Vulgaris Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Pemphigus Vulgaris market<\/strong> or expected to get launched in the market during the study period. The analysis covers Pemphigus Vulgaris market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Pemphigus Vulgaris Pipeline Development Activities<\/strong> and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pemphigus-vulgaris-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Pemphigus Vulgaris Therapeutics Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Pemphigus Vulgaris (PV) Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Principia Biopharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topas Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Argenx BVBA<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Pemphigus Vulgaris (PV) Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">TPM203<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ARGX-113\/Efgartigimod<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rilzabrutinib\/PRN 1008<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>The approval of emerging products is expected to significantly impact the Pemphigus Vulgaris (PV) market during the forecast period.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get the sample copy of the report, at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pemphigus-vulgaris-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pemphigus-vulgaris-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Pemphigus Vulgaris Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Pemphigus Vulgaris Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Pemphigus Vulgaris Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Pemphigus Vulgaris Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Pemphigus Vulgaris Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Pemphigus Vulgaris Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pemphigus Vulgaris Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Pemphigus Vulgaris Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Pemphigus Vulgaris Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Pemphigus Vulgaris Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Pemphigus Vulgaris Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Pemphigus Vulgaris Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Pemphigus Vulgaris Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Pemphigus Vulgaris Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Pemphigus Vulgaris Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Pemphigus Vulgaris Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request Sample Report here:-&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pemphigus-vulgaris-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pemphigus-vulgaris-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pemphigus-vulgaris-market-is-expected-to-showcase-a-significant-growth-by-2032-estimates-delveinsight-key-companies-principia-biopharma-topas-therapeutics-and-argenx-bvba\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pemphigus-vulgaris-market-is-expected-to-showcase-a-significant-growth-by-2032-estimates-delveinsight-key-companies-principia-biopharma-topas-therapeutics-and-argenx-bvba\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Pemphigus Vulgaris Market Size and Share in the 7MM (i.e. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pemphigus-vulgaris-market-is-expected-to-showcase-a-significant-growth-by-2032-estimates-delveinsight-key-companies-principia-biopharma-topas-therapeutics-and-argenx-bvba_584757.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-584757","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/584757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=584757"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/584757\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=584757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=584757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=584757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}